Franklin Resources
CRSP icon

Franklin Resources’s CRISPR Therapeutics CRSP Stock Holding History

Franklin Resources’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.35M Buy
28,381
+3,835
+16% +$202K ﹤0.01% 2070
2025
Q4 		$1.29M Sell
24,546
-1,271
-5% -$76.1K ﹤0.01% 1976
2025
Q3 		$1.67M Buy
25,817
+18,217
+240% +$1.05M ﹤0.01% 1852
2025
Q2 		$370K Buy
7,600
+165
+2% +$6.38K ﹤0.01% 2466
2025
Q1 		$253K Buy
7,435
+429
+6% +$18.2K ﹤0.01% 2562
2024
Q4 		$276K Sell
7,006
-91
-1% -$4.3K ﹤0.01% 2539
2024
Q3 		$339K Buy
7,097
+800
+13% +$40.6K ﹤0.01% 2445
2024
Q2 		$340K Buy
6,297
+23
+0.4% +$1.33K ﹤0.01% 2390
2024
Q1 		$428K Buy
6,274
+319
+5% +$22.8K ﹤0.01% 2321
2023
Q4 		$373K Sell
5,955
-227,444
-97% -$12.6M ﹤0.01% 2077
2023
Q3 		$10.6M Buy
233,399
+201
+0.1% +$10.4K 0.01% 903
2023
Q2 		$13.1M Buy
233,198
+35
+0% +$1.99K 0.01% 867
2023
Q1 		$10.5M Sell
233,163
-60,908
-21% -$2.96M 0.01% 919
2022
Q4 		$12M Sell
294,071
-1,901
-0.6% -$101K 0.01% 901
2022
Q3 		$19.3M Buy
295,972
+3,326
+1% +$241K 0.01% 772
2022
Q2 		$17.8M Sell
292,646
-313
-0.1% -$18.4K 0.01% 817
2022
Q1 		$18.4M Sell
292,959
-19,544
-6% -$1.23M 0.01% 875
2021
Q4 		$23.7M Sell
312,503
-6,712
-2% -$586K 0.01% 845
2021
Q3 		$35.7M Buy
319,215
+2,525
+0.8% +$317K 0.01% 749
2021
Q2 		$51.3M Sell
316,690
-512,664
-62% -$62.3M 0.02% 647
2021
Q1 		$101M Buy
829,354
+4,292
+0.5% +$648K 0.04% 435
2020
Q4 		$126M Sell
825,062
-76,751
-9% -$9.07M 0.05% 361
2020
Q3 		$75.4M Buy
901,813
+2,292
+0.3% +$203K 0.04% 462
2020
Q2 		$83.6M Buy
899,521
+456,574
+103% +$26.7M 0.04% 423
2020
Q1 		$18.8M Buy
442,947
+7,303
+2% +$377K 0.01% 684
2019
Q4 		$26.5M Buy
435,644
+11,031
+3% +$602K 0.01% 702
2019
Q3 		$17.4M Hold
424,613
– – 0.01% 775
2019
Q2 		$20M Hold
424,613
– – 0.01% 750
2019
Q1 		$15.2M Sell
424,613
-54,750
-11% -$1.89M 0.01% 794
2018
Q4 		$13.7M Hold
479,363
– – 0.01% 808
2018
Q3 		$21.3M Sell
479,363
-242,420
-34% -$12.7M 0.01% 770
2018
Q2 		$42.4M Buy
721,783
+10,050
+1% +$573K 0.02% 573
2018
Q1 		$32.5M Sell
711,733
-82,800
-10% -$3.42M 0.02% 654
2017
Q4 		$18.7M Buy
794,533
+65,200
+9% +$1.24M 0.01% 809
2017
Q3 		$13M Hold
729,333
– – 0.01% 889
2017
Q2 		$11.7M Hold
729,333
– – 0.01% 913
2017
Q1 		$15.7M Hold
729,333
– – 0.01% 854
2016
Q4 		$14.4M Buy
+729,333
New +$13.6M 0.01% 869

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $23.7B AUM 65.43% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
GP
GSK plc London $599M AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $915M AUM 209.71% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Franklin Resources's CRSP Position: Q1 2026 in Review

Franklin Resources increased its CRISPR Therapeutics (CRSP) stake by 16% in Q1 2026, buying an estimated $202K and bringing the position to 28,381 shares worth $1.35M. The position accounts for ﹤0.01% of the portfolio, ranked #2070.

Franklin Resources first reported a position in CRSP in Q4 2016 and has held it in 38 quarters since. The position peaked at $126M in Q4 2020. 488 funds tracked by Wall St. Rank hold CRSP as of Q1 2026.

  • Franklin Resources held 28,381 shares of CRISPR Therapeutics worth $1.35M as of Q1 2026.
  • Franklin Resources bought 3,835 CRISPR Therapeutics shares in Q1 2026, an estimated $202K.
  • CRISPR Therapeutics made up ﹤0.01% of Franklin Resources's portfolio in Q1 2026, its #2070 holding.
  • Franklin Resources first reported a position in CRISPR Therapeutics in Q4 2016 and has held it in 38 quarters since.
  • Franklin Resources's CRISPR Therapeutics position peaked at $126M in Q4 2020.
  • 488 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q1 2026.

Based on Franklin Resources's 13F filing for Q1 2026, filed 13 May 2026.